



2<sup>nd</sup> Familial Mediterranean  
Fever Meeting

FMF 2024

**Program**

**May 3, 2024 (Friday)**

GMT + 3		
<b>16.00-18.00</b>	<b>Session 1 - Old paradigms, new concepts</b>	<b>Chairpersons:</b> Hasan Yazıcı ( <i>Türkiye</i> ), Isabelle Touitou ( <i>France</i> )
16.00-16.20	Unmet needs in FMF	Huri Özdoğan ( <i>Türkiye</i> )
16.20-16.50	Old paradigms and new concepts in FMF	Eldad Ben-Chetrit ( <i>Israel</i> )
16.50-17.20	What is FMF?	Ahmet Gül ( <i>Türkiye</i> )
17.20-17.50	Review of the last two year	Yelda Bilginer ( <i>Türkiye</i> )
19.00	Welcome Reception	

**May 4, 2024 (Saturday)**

GMT + 3		
<b>08.00 - 10.00</b>	<b>Session 2 - Update: Genetics and Pathogenesis</b>	<b>Chairpersons:</b> Ahmet Gül ( <i>Türkiye</i> ), Tillmann Kallinich ( <i>Germany</i> ), Banu Peynircioğlu ( <i>Türkiye</i> )
08.00-08.30	The changing concept of one gene-one phenotype in monogenic autoinflammatory diseases	Ivona Aksentijevich ( <i>USA</i> )
08.30-09.00	Regulation of pyrin inflammasome	Mohamed Lamkanfi ( <i>Belgium</i> )
09.00-09.20	Pyroptosis and clinical implications in FMF	Helmut Wittkowski ( <i>Germany</i> )

09.20-09.40	Pyrin inflammasome and inflammatory cell migration in FMF	Tayfun Hilmi Akbaba (Türkiye)
09.40-10.00	Discussion	
<b>10.00-10.30</b>	<b>Coffee Break</b>	
<b>10.30-12.00</b>	<b>Session 3 - Update: Genetic diagnosis, environmental factors and microbiome</b>	<b>Chairpersons:</b> Seza Özen (Türkiye), Dorota Rowczenio (UK)
10.30-11.00	Update: genetic diagnosis in FMF	Isabelle Touitou (France)
11.00-11.20	Non-MEFV gen variants in patients with a FMF phenotype	Eda Tahir Turanlı (Türkiye)
11.20-11.40	Syndrome of Undifferentiated Recurrent Fever (SURF)	Marco Gattorno (Italy)
11.40-12.00	Impact of environmental factors and microbiome on the pathogenesis of FMF	Sophie Georjin Lavielle (France)
<b>12.00-12.30</b>	<b>Oral presentations</b>	<b>Chairpersons:</b> Fatoş Önen (Türkiye), Ömer Karadağ (Türkiye)
12.00-12.07	A clinical overview of unclassified systemic autoinflammatory diseases followed in a Turkish Pediatric Referral Center (Ref: 115)	Şengül Çağlayan (Türkiye)
12.07-12.14	Evaluation of patients carrying variants of unknown significance (VUS) in a large FMF cohort: A single center study (Ref: 116)	Taner Coşkuner (Türkiye)
12.14-12.21	Exploring S100A8/A9, Neopterin, and MMP3 in Familial Mediterranean Fever: Insights into pathogenesis and diagnostic significance (Ref: 145)	Özgür Can Kılınc (Türkiye)
12.21-12.28	Epidemiological features and clinical manifestations in Lebanese and Italian subjects with Familial Mediterranean Fever (Ref: 130)	Nour Jaber (Italy)
<b>12.30-13.30</b>	<b>Lunch &amp; Poster Reviewing</b>	
<b>13.30-15.30</b>	<b>Session 4 - Criteria, registry, geography</b>	<b>Chairpersons:</b> Helmut Wittkowski (Germany), Fatoş Yalçınkaya (Türkiye)
13.30-13.50	Pros and cons of diagnostic and classification criteria for FMF	Isabelle Kone-Paut (France)

13.50-14.10	Challenges of preparing a registry for FMF	Marco Gattorno ( <i>Italy</i> )
14.10-14.20	Discussion	
<b>14.20-15.30</b>	<b>Round Table: FMF around the world</b>	<b>Chairpersons:</b> Seza Özen ( <i>Türkiye</i> ), Huri Özdoğan ( <i>Türkiye</i> ), Eldad Ben-Chetrit ( <i>Israel</i> )
14.20-14.35	FMF in Japan	Tomohiro Koga ( <i>Japan</i> )
14.35-14.50	FMF in Italy	Raffaele Manna ( <i>Italy</i> )
14.50-15.05	FMF in Saudi Arabia	Sulaiman Al-Mayouf ( <i>Saudi Arabia</i> )
15.05-15.30	Discussion	
<b>15.30-16.00</b>	<b>Coffee Break</b>	
<b>16.00-17.40</b>	<b>Session 5 - Update: Amyloidosis, associated diseases</b>	Helen Lachmann ( <i>UK</i> ), Cengiz Korkmaz ( <i>Türkiye</i> ), Melike Melikoğlu ( <i>Türkiye</i> )
16.00-16.20	Is amyloidosis still a threat in FMF?	Ahmet Gül ( <i>Türkiye</i> )
16.20-16.40	Early versus late onset FMF	Piero Portincasa ( <i>Italy</i> )
16.40-17.00	PFAPA and FMF	Özgür Kasapçopur ( <i>Türkiye</i> )
17:00-17.20	AS and enthesitis in FMF	Servet Akar ( <i>Türkiye</i> )
17.20-17.40	Behçet's disease and FMF	Emire Seyahi ( <i>Türkiye</i> )
<b>17.40-18.08</b>	<b>Oral presentations</b>	<b>Chairpersons:</b> Mikail Kostik ( <i>Russia</i> ), Hakan Babaoğlu ( <i>Türkiye</i> )
17.40-17.47	Gender differences in the diagnosis delay of familial Mediterranean fever: A JIR cohort study (Ref: 91)	Rim Bourguiba ( <i>Tunisia</i> )
17.47-17.54	Cardiovascular comorbidities in patients with Familial Mediterranean Fever over 45 years of age (Ref: 133)	Sejla Karup ( <i>Türkiye</i> )
17.54-18.01	Male fertility and paternal effect on pregnancy outcomes in FMF (Ref: 150)	Kerem Parlar ( <i>Türkiye</i> )
18.01-18.08	Menstrual cycle patterns and dysmenorrhea frequency in adolescent girls with familial Mediterranean fever: Cross-Sectional case-control study (Ref: 106)	Fatma Gül Demirkan ( <i>Türkiye</i> )

**May 5, 2024 (Sunday)**

GMT + 3		
<b>08.00-10.00</b>	<b>Session 6a. - Update: Treatment-I</b>	<b>Chairpersons:</b> Huri Özdoğan(Türkiye), Sophie Georgin-Lavialle (France), Serdal Uğurlu (Türkiye)
08.00-08.20	Mechanism of action of colchicine and its expanding efficacy	Eldad Ben-Chetrit (Israel)
08.20-08.40	Colchicine response and tolerance in FMF	Seza Özen (Türkiye)
08.40-09.00	Anti-IL1 treatment in FMF	Serdal Uğurlu (Türkiye)
09.00-09.15	On-demand anti-IL1 treatment	Ilan Ben-Zvi (Israel)
09.15-09.40	Efficacy and safety of anti-IL1 $\beta$ treatment in FMF	Helen Lachmann (UK)
09.40-10.00	Anti-IL6 treatment FMF	Tomohiro Koga (Japan)
<b>10.00-10.30</b>	<b>Coffee Break</b>	
<b>10.30-12.30</b>	<b>Session 6b. - Update: Treatment II</b>	<b>Chairpersons:</b> Ahmet Gül(Türkiye), Isabelle Kone-Paut (France)
10.30-10.50	Biologic agent combinations in the management of FMF and other autoinflammatory diseases	Abdurrahman Tufan (Türkiye)
10.50-11.10	Treat-to target strategies in FMF	Tillmann Kallinich (Germany)
11.10-11.40	Discussion for sessions 6a and 6b	
<b>11.40-12.30</b>	<b>Session 7 - Transition</b>	<b>Chairpersons:</b> Kenan Barut (Türkiye), Gülay Özgön(Türkiye), Amra Adrovich (Türkiye)
11.40-12.00	Transition from pediatric to adult FMF clinics	Betül Sözeri (Türkiye)
<b>12.00-12.42</b>	<b>Oral presentations</b>	
12.00-12.07	Machine learning algorithms to predict colchicine resistance in Familial Mediterranean Fever (Ref: 158)	Admir Öztürk (Türkiye)

12.07-12.14	Comparing the effects of treatments during the attack period on clinical and laboratory data in Familial Mediterranean Fever Patients (Ref: 143)	Elif Kılıç Konte ( <i>Türkiye</i> )
12.14-12.21	Familial Mediterranean Fever: Effective follow-up of patients who ceased colchicine treatment (Ref: 122)	Gülcan Özomay Baykal ( <i>Türkiye</i> )
12.21-12.28	Canakinumab treatment in patients with colchicine-resistant familial Mediterranean fever: a multicenter observational study (Ref: 83)	Mete Kara ( <i>Türkiye</i> )
12.28-12.35	Is canakinumab a good tool for the undifferentiated autoinflammatory diseases: the data of retrospective cohort study (Ref: 108)	Mikhail Kostik ( <i>Russia</i> )
12.35-12.42	Familial Mediterranean Fever from childhood to adulthood (Ref: 163)	Zeynep Balık ( <i>Türkiye</i> )
12.42-12.50	Discussion	
12.50-13.10	Highlights of the meeting	Sezgin Şahin ( <i>Türkiye</i> )
<b>13.10-13.30</b>	<b>Future perspectives, presentation of awards, closing remarks</b>	Huri Özdoğan ( <i>Türkiye</i> ), Eldad Ben-Chetrit ( <i>Israel</i> ), Serdal Uğurlu ( <i>Türkiye</i> )



### **D Event Tourism Organization**

Professional Congress Organizer (PCO)

İçerenköy Mah. Çayır Cad. No:5 Bay Plaza Kat:12

Ataşehir, İstanbul

Phone: +90 216 573 18 36

Web: [www.devent.com.tr](http://www.devent.com.tr)

e-mail: [istanbul@devent.com.tr](mailto:istanbul@devent.com.tr)

D Event Tourism Organization